CIK 0001125345 · Pharmaceutical Preparations (SIC 2834) · Nasdaq · incorporated in DE · fiscal year ends 12/31
| FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|
| Revenue (USD) | 149.5 M | 151.9 M | ||
| Net income (USD) | -119.8 M | -202.1 M | -129.7 M | |
| Diluted EPS (USD/shares) | -1.18 | -1.95 |
| Filed | Form | Description | Period |
|---|---|---|---|
| 2026-10-07 | 4 | FORM 4 | 2026-10-06 |
| 2026-09-21 | 144 | 144 | |
| 2026-09-03 | S-8 | S-8 | |
| 2026-09-03 | 8-K/A | 8-K/A items 9.01 | 2026-09-03 |
| 2026-08-20 | 4 | FORM 4 | 2026-08-19 |
| 2026-08-19 | 144 | 144 | |
| 2026-08-18 | 4 | FORM 4 | 2026-08-17 |
| 2026-08-17 | 144 | 144 | |
| 2026-08-14 | 10-Q | 10-Q | 2026-06-30 |
| 2026-08-14 | SCHEDULE 13G/A | SCHEDULE 13G/A | |
| 2026-08-13 | 8-K | 8-K items 2.02,9.01 | 2026-08-13 |
| 2026-08-03 | 144 | 144 | |
| 2026-08-03 | SCHEDULE 13G/A | SCHEDULE 13G/A | |
| 2026-07-29 | SCHEDULE 13G | SCHEDULE 13G | |
| 2026-07-23 | 8-K | 8-K items 8.01 | 2026-07-23 |
| 2026-07-20 | SCHEDULE 13G/A | SCHEDULE 13G/A | |
| 2026-07-13 | 144 | 144 | |
| 2026-07-08 | 8-K | 8-K items 5.02 | 2026-07-01 |
| 2026-07-07 | 8-K | 8-K items 2.01,7.01,9.01 | 2026-06-30 |
| 2026-06-05 | SCHEDULE 13G | SCHEDULE 13G | |
| 2026-05-20 | 4 | FORM 4 | 2026-05-18 |
| 2026-05-20 | 4 | FORM 4 | 2026-05-18 |
| 2026-05-20 | 4 | FORM 4 | 2026-05-18 |
| 2026-05-20 | 4 | FORM 4 | 2026-05-18 |
| 2026-05-20 | 4 | FORM 4 | 2026-05-18 |
Forms on file (last 1,000): 4 433, 8-K 146, SC 13G/A 64, 10-Q 39, 3 32, SC 13G 30, SCHEDULE 13G/A 18, 144 16. Source: SEC EDGAR, as filed; this page is public data and not investment advice.
GET https://store.agentexchange.work/gw/filings/company?ticker=MGNX (0.002 USD), /gw/filings/filings?ticker=MGNX&form=8-K, /gw/filings/facts?ticker=MGNX&concept=Revenues, full-text /gw/filings/search?q=.... Pay per call in USDC (x402) or with a 19 USD card key for 1,000 calls. Catalogue · llms.txtUpdated from EDGAR within 30 minutes of a filing. Agent Exchange